Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Macro

Trump’s Drug-Pricing Plan Could Raise Global Costs and Limit Access to Medicines

by Team Lumida
May 16, 2025
in Macro
Reading Time: 4 mins read
A A
0
Tech Titans Pivot: Silicon Valley’s New Alliance in Trump’s Second Term

"Donald Trump" by Gage Skidmore is licensed under CC BY-SA 2.0

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  • President Trump’s drug-pricing plan aims to align U.S. drug costs with lower prices abroad, but experts warn it could lead to higher prices in Europe and reduced access in lower-income countries.
  • Wealthy European nations like Germany and Norway are expected to feel the impact first, with ripple effects on smaller markets in Central and Eastern Europe.
  • Drugmakers may delay or avoid launching new medicines in lower-cost markets to maintain higher U.S. prices, potentially harming global access to innovative treatments.
  • The plan relies on voluntary action and lacks specifics for implementation, raising questions about its feasibility and long-term impact.

What Happened?

President Trump signed an executive order on May 12 to reduce U.S. drug prices by benchmarking them to lower prices paid in other countries, a practice known as reference pricing. While the plan aims to ease the financial burden on Americans, it could have unintended global consequences.

Pharmaceutical companies may respond by raising drug prices in Europe and other markets to maintain elevated U.S. prices. Wealthy European nations, which often receive new medicines soon after the U.S., are likely to be affected first. In lower-income countries, companies may delay or avoid launching new drugs altogether, limiting access to life-saving treatments.

The Trump administration argues that higher global drug prices would fund pharmaceutical innovation, which it claims is disproportionately financed by U.S. consumers. However, the plan’s reliance on voluntary action and lack of implementation details have drawn criticism from industry experts.


Why It Matters?

Trump’s drug-pricing plan could disrupt global pharmaceutical markets, with significant implications for access to medicines and healthcare costs. Wealthy nations may face higher prices, while lower-income countries risk losing access to new treatments altogether.

The plan also highlights the complexities of implementing reference pricing in the U.S., where drugmakers are unlikely to voluntarily disclose negotiated discounts. If poorly executed, the policy could exacerbate global health inequities and strain international relations.

For the pharmaceutical industry, the plan poses a challenge to balancing profitability with equitable access. Companies like Roche have already warned that the policy could jeopardize U.S. investments in research and development.


What’s Next?

The Trump administration will need to address the logistical challenges of implementing reference pricing, including securing voluntary price disclosures from drugmakers. Meanwhile, European nations may need to reassess their pricing strategies to mitigate the impact of higher drug costs.

Global health organizations and policymakers will likely push for solutions that balance affordability with innovation, such as value-based pricing models. Investors and industry stakeholders should monitor the policy’s rollout and its potential impact on pharmaceutical markets and healthcare access worldwide.

Source
Tags: Trump
Previous Post

Walmart’s Tariff-Driven Price Hikes Signal Broader Inflationary Pressures Across Industries

Next Post

Musk’s xAI Blames Unauthorized Tampering for Controversial ‘White Genocide’ Responses

Recommended For You

Trump’s U-Turn on China Buying Iranian Oil Sparks Confusion Amid Sanctions Policy

by Team Lumida
9 hours ago
Trump Announces 25% Tariffs on Mexico and Canada, Targeting Border Security and Trade

Key Takeaways: Powered by lumidawealth.com President Donald Trump announced on social media that China can continue purchasing oil from Iran, surprising oil traders and U.S. officials and potentially undermining...

Read more

Israel-Iran Conflict Revives China’s Interest in Russian Gas Pipeline Amid Energy Security Concerns

by Team Lumida
9 hours ago
Israel-Iran Conflict Revives China’s Interest in Russian Gas Pipeline Amid Energy Security Concerns

Key Takeaways: Powered by lumidawealth.com The Israel-Iran conflict has prompted China to reconsider the stalled Power of Siberia 2 gas pipeline project with Russia, seeking alternatives to Middle Eastern...

Read more

China Poised for Over 100 AI Breakthroughs, Ex-Official Predicts, Amid Growing U.S. Rivalry

by Team Lumida
1 day ago
China’s Bold Economic Moves: What You Need to Know Now

Key Takeaways: Powered by lumidawealth.com Former Chinese central bank official Zhu Min predicts China will achieve over 100 AI breakthroughs in the next 18 months, transforming its economy and...

Read more

Israel and Iran Agree to Ceasefire After Trump Brokers Truce to End Conflict

by Team Lumida
1 day ago
six fighter jets

Key Takeaways: Powered by lumidawealth.com U.S. President Donald Trump announced a ceasefire between Israel and Iran after escalating tensions and missile strikes from both sides. The truce was brokered...

Read more

Supreme Court Allows Trump Administration to Expedite Deportations to Third Countries

by Team Lumida
1 day ago
Supreme Court Allows Trump Administration to Expedite Deportations to Third Countries

Key Takeaways: Powered by lumidawealth.com The Supreme Court ruled in favor of the Trump administration, allowing the swift deportation of migrants to third-party countries without requiring meaningful notice of...

Read more

Shipping Industry on High Alert After US Strikes on Iran’s Nuclear Facilities

by Team Lumida
2 days ago
red and blue cargo ship on body of water during daytime

Key Takeaways: Powered by lumidawealth.com Greece has advised its shipowners to reassess passage through the Strait of Hormuz, citing heightened risks of Iranian retaliation following US airstrikes. Naval forces...

Read more

U.S. Urges China to Dissuade Iran from Closing Strait of Hormuz Amid Escalating Tensions

by Team Lumida
3 days ago
U.S. Struggles to Break China’s Grip on Critical Minerals as Syrah Resources Faces Setbacks

Key Takeaways: Powered by lumidawealth.com U.S. Secretary of State Marco Rubio called on China to leverage its influence over Iran to prevent the closure of the Strait of Hormuz,...

Read more

China Condemns US Strikes on Iran, Calls for Ceasefire and Middle East Peace

by Team Lumida
3 days ago
China’s Bold Economic Moves: What You Need to Know Now

Key Takeaways: Powered by lumidawealth.com China strongly condemned the US airstrikes on Iranian nuclear facilities, stating they violate the UN Charter and international law while escalating Middle East tensions....

Read more

Trump Signals Two-Week Delay on Iran Strike to Explore Diplomatic Options

by Team Lumida
5 days ago
Fed Official Warns of Inflation Risks Under Trump Presidency

Key Takeaways: Powered by lumidawealth.com President Trump announced he will decide within two weeks whether to strike Iran, signaling a pause to allow for potential diplomatic negotiations. Israel has...

Read more

Canada Imposes Steel Import Curbs to Counter Fallout from Trump’s Tariffs

by Team Lumida
5 days ago
flag of Canada

Key Takeaways: Powered by lumidawealth.com Canada is introducing import quotas and considering higher tariffs on U.S. steel and aluminum to protect its domestic metals sector, destabilized by Trump’s 50%...

Read more
Next Post
Musk and Trump’s Friendship: What It Means for the EV Market

Musk’s xAI Blames Unauthorized Tampering for Controversial ‘White Genocide’ Responses

Fed Official Warns of Inflation Risks Under Trump Presidency

Trump’s 30% China Tariffs Likely to Stay Until Late 2025, Analysts Predict

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Major Tech Platforms Face Malaysian Licensing Deadline as X and Google Hold Out

Elon Musk’s xAI Acquires X (Formerly Twitter) in $33 Billion Deal, Creating $100 Billion AI-Social Media Giant

March 29, 2025
Bitcoin Could Drop to $50K Before a Potential Fed-Driven Rally

Bitcoin Nears $86K as XRP Surges on SEC Resolution and U.S. Futures Launch

March 20, 2025
selective focus photo of Bitcoin near monitor

Trump’s Bitcoin Reserve Order Sparks Market Decline Amid Investor Disappointment

March 7, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018